- Featured Product
- KD/KO Validated
TRIM22 Polyclonal antibody
TRIM22 Polyclonal Antibody for IHC, ELISA
Host / Isotype
Rabbit / IgG
Reactivity
human
Applications
WB, IHC, IF, ELISA
Conjugate
Unconjugated
Cat no : 13744-1-AP
Synonyms
Validation Data Gallery
Tested Applications
Positive IHC detected in | human lung cancer tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
Recommended dilution
Application | Dilution |
---|---|
Immunohistochemistry (IHC) | IHC : 1:300-1:1200 |
Sample-dependent, check data in validation data gallery |
Published Applications
KD/KO | See 4 publications below |
WB | See 5 publications below |
IHC | See 2 publications below |
IF | See 1 publications below |
Product Information
13744-1-AP targets TRIM22 in WB, IHC, IF, ELISA applications and shows reactivity with human samples.
Tested Reactivity | human |
Cited Reactivity | human |
Host / Isotype | Rabbit / IgG |
Class | Polyclonal |
Type | Antibody |
Immunogen | TRIM22 fusion protein Ag4683 |
Full Name | tripartite motif-containing 22 |
Calculated molecular weight | 498 aa, 57 kDa |
Observed molecular weight | 50 kDa |
GenBank accession number | BC035582 |
Gene symbol | TRIM22 |
Gene ID (NCBI) | 10346 |
Conjugate | Unconjugated |
Form | Liquid |
Purification Method | Antigen affinity purification |
Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol pH 7.3. |
Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. |
Protocols
Product Specific Protocols | |
---|---|
IHC protocol for TRIM22 antibody 13744-1-AP | Download protocol |
Standard Protocols | |
---|---|
Click here to view our Standard Protocols |
Publications
Species | Application | Title |
---|---|---|
Nat Commun Identification of DAXX as a restriction factor of SARS-CoV-2 through a CRISPR/Cas9 screen. | ||
Oncotarget TRIM22 confers poor prognosis and promotes epithelial-mesenchymal transition through regulation of AKT/GSK3β/β-catenin signaling in non-small cell lung cancer.
| ||
Front Cell Infect Microbiol Constitutive TRIM22 Expression in the Respiratory Tract Confers a Pre-Existing Defence Against Influenza A Virus Infection.
| ||
Cell Biol Int TRIM22 knockdown suppresses chronic myeloid leukemia via inhibiting PI3K/Akt/mTOR signaling pathway.
| ||
Transl Cancer Res FOXO3/TRIM22 axis abated the antitumor effect of gemcitabine in non-small cell lung cancer via autophagy induction.
|